-
09 January 2018
-
09 January 2018
Ipsen Biopharmaceuticals Canada Inc. Announces Health Canada Approval of DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Children Aged Two and Older
— Approval is based on the first large-scale neurotoxin trial to demonstrate meaningful functional improvement in pediatric lower limb spasticity1—...
-
05 September 2017
-
05 September 2017
Ipsen Biopharmaceuticals Canada Names Paul Reider Country Manager and Joins Innovative Medicines Canada to Drive Development and Delivery of Key Therapies
MISSISSAUGA, ON, September 5, 2017 – Ipsen Biopharmaceuticals Canada Inc., an affiliate of Ipsen SA (Euronext: IPN; ADR: IPSEY), an emerging global biopharmaceutical company, today announced that it has joined the Innovative Medicines Canada (IMC) a...